Yarrow (YARW) stock price, chart and financials
Price chart
Financials
- Revenue (trailing twelve months)
- $482,000.00
- Revenue (quarter)
- $97,000.00
- Gross profit (trailing twelve months)
- $482,000.00
- Gross margin
- 100.00%
- Net income (quarter)
- −$3.0M
- Net margin
- −3881.54%
- Return on equity
- −61.40%
- EPS (trailing twelve months)
- −$21.86
- Book value per share
- $33.04
- Price to book
- 7.57
- Debt to assets
- 6.53%
- Dividend yield
- 8.04%
Company profile
Yarrow Bioscience Inc is a clinical-stage biopharmaceutical company focused on developing biotherapeutics for autoimmune thyroid diseases. Its flagship product candidate, YB-101 (also known as GenSci098), is a humanized, monoclonal antibody targeting the thyroid-stimulating hormone receptor, which Yarrow plans to develop for the treatment of Graves' disease (GD) and potentially thyroid eye disease (TED). The company has one reportable segment relating to the research and development of its research programs, GD and TED.
Frequently asked questions
Is Yarrow (YARW) profitable?
No. Yarrow reported a net loss of $18.7M over the trailing twelve months.
How much revenue does Yarrow (YARW) make?
Yarrow generated $482,000.00 in revenue over the trailing twelve months, up 40.58% year over year.
How do I buy stock in Yarrow (YARW)?
YARW trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.
Quotes and charts are not real-time and must not be relied on for trade decisions or valuation.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.